Skip to main content
Publications
Johannes CB, Ziemiecki R, Pladevall-Vila M, Kosvesdy CP, Ebert N, Thomsen RWW, Christiansen CF, Baak B, Cabaninas CR, Kashihara N, Yano Y, Kanegae H, Coleman CI, Okami S, Li u F, Layton JB, Vizcaya D, Oberprieler NG. Use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease: a multicountry report from the FOUNTAIN platform. Poster presented at the 2024 ISPE Annual Meeting; August 26, 2024. Berlin, Germany.
Oberprieler NG, Kovesdy CP, Layton JB, Gay A, Farjat AE, Liu F, Johannes CB, Pladevall-Vila M, Vizcaya D. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis. Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M, Johannes C, Saigi-Morgui N, Ziemiecki R, Layton J, Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform. Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.
Beau-Lejdstrom R, Hong LS, Garcia de ALbeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0
Flythe JE, Forfang D, Gedney N, White DM, Wilkie C, Cavanaugh K, Harris RC, Unruh M, Squillaci G, West M, Mansfield C, Soloe CS, Treiman K, Wood D, Hurst FP, Neuland C, Saha A, Sheldon M, Tarver ME. Development of a patient preference survey for wearable kidney replacement therapy devices. Kidney360. 2022 May 5;3(7):1197-209. doi: 10.34067/KID.0001862022